Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEARTRIP Study: Yangxinshi Pian versus trimetazidine after PCI
CTR20210171Phase 4Active
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Aug 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 4 trial of yangxinshi, trimetazidine in coronary arteriosclerosis, angina pectoris, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Aug 2019; status: active.
02
Drugs
yangxinshitrimetazidine
03
Conditions
coronary arteriosclerosisangina pectoris
Beyond the preview
Go deeper on CTR20210171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210171.